spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioGenes Establishes Scientific Advisory Board

BioGenes GmbH


Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:

  • Prof. Dr. Hans Henning von Horsten, Industrial Biomanufacturing, HTW-Berlin University of
  • Applied Sciences, Berlin
  • Prof. Dr. Frank F. Bier, Dept. Biosystems Integration and Process Automatisation, Fraunhofer
  • IZI-BB, Potsdam-Golm
  • Dr. Wieland Wolf, CEO ProBioGen AG, Berlin
  • Dr. Jens Knauer, Method Development Virology Testing Quality Control, IDT Biologika GmbH, Dessau-Rosslau
The Scientific Advisory Board will provide BioGenes with significant expertise and experience throughout the whole drug development and manufacturing value chain to help strengthen and extend the Company’s position in the field of quality control for biopharmaceuticals.

Dr. Alexander Knoll, Managing Director of BioGenes states: “We are pleased to welcome these renowned experts to BioGenes’ Scientific Advisory Board. Creating the SAB represents another important step forward for the Company. Its members bring a wealth of experience in the area of biomanufacturing and analytics and will provide crucial advice based on their specializations which will be essential to guide us in prioritizing and driving forward our goals.”

Prof. Dr. Hans Henning von Horsten is co-inventor of several patents and pending patent applications for the biomanufacturing business. He was among the key inventors of ProBioGen’s GlymaxX antibody engineering technology that was outlicensed to Boehringer-Ingelheim, Novartis, Thermo-Fisher Scientific and several other drug developers. Hans Henning von Horsten is also Head of the Working Group Biotechnology at the Berlin-Brandenburg branch of the VDI Association of German Engineers.

Prof. Dr. Frank F. Bier is the founder of the Molecular Bioanalytics branch of the Fraunhofer Institute
for Biomedical Engineering (Fraunhofer IBMT). In 2003, he was appointed Chair of Applied
Bioelectronics and Biochip Technology at the University of Potsdam. Since 2014 he is the Head of the
Department Biosystems Integration and Process Automatisation of the newly formed branch
Fraunhofer Institute for Cell Therapy and Immunology, Biotechnology and Bioproduction (Fraunhofer
IZI-BB) in Potsdam-Golm, Germany.

Dr. Wieland Wolf is the CEO of ProBioGen, an internationally operating Contract Development and Manufacturing Organization (CDMO). He has three decades of experience in the biopharmaceutical industry. Wieland Wolf was involved in pioneering product registrations at Bioferon GmbH, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organization (CMO). Wieland Wolf is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer IGB) in Stuttgart, Germany.

Dr. Jens Knauer has a strong background in GLP/GMP contract research, method development and as a Principal Investigator in several clinical trials. Before joining IDT Biologika GmbH, he was involved in the development and validation of immunological assays at the Fraunhofer Institute for Cell Therapy and Immunology where he was also instrumental in building a GLP laboratory for immunotoxicological assays.

About BioGenes
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay
development and is an experienced and reliable partner for process development improvements in all
areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international
requirements and regularities of quality assurance and animal welfare. The Company maintains longterm
relationships with research institutes, universities and biotech and pharmaceutical companies,
including eight of the ten largest pharmaceutical companies in the world. The company has been
evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP
assay development.

phone +49 (0)30 6576 2396
email service@biogenes.de
web www.biogenes.de
email Koepenicker Str. 325 D-12555 Berlin Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

RWS Life Sciences Welcomes New VP of Quality

RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice President, Global Quality and Process, in charge of the strategic direction and implementation of its Quality system, underlying organizational processes, and change management.
More info >>


White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

Industry Events

Outsourcing Clinical Trials Nordics 2018

30-31 October 2018, Copenhagen, Denmark

Following on from the success of the 2017 Outsourcing in Clinical Trials Nordics conference, Arena International is pleased to announce that the event will return for its 6th year in 2018. The 2018 event welcomes biopharmaceutical and medical device companies from across the Nordic region to share knowledge and challenges of outsourcing and clinical operations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement